An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

Clinical trial NCT02604433 · COMPLETED

Trial details

NCT number: NCT02604433
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Erythrocyte Transfusion Beta-Thalassemia

Start date: 2016-05-02
Primary completion: 2021-01-05
Enrollment: 336

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.